FDA Center for Drug Evaluation & Research Issues Warning Letter to Jabil Inc.
September 02, 2026
September 02, 2026
WASHINGTON, Sept. 2 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Jabil Inc. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Michael Dastoor, Chief Executive Officer and Director, Jabil Inc., 10800 Roosevelt Blvd. N., St. Petersburg, FL 33716, United States, (b)(4)
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING . . .
* * *
Recipient: Mr. Michael Dastoor, Chief Executive Officer and Director, Jabil Inc., 10800 Roosevelt Blvd. N., St. Petersburg, FL 33716, United States, (b)(4)
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING . . .